2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: MD12

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent

Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: Neuromyelitis optica spectrum disorder (NMOSD) relapses can cause significant and irreversible neurologic disability. In...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More →

Platform-Neuroimaging

October 25, 2021

International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS

Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC